Item type: | Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Journal or Publication Title: | Clinical cancer research : an official journal of the American Association for Cancer Research | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publisher: | AMER ASSOC CANCER RESEARCH | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Place of Publication: | PHILADELPHIA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Volume: | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Issue or Book Chapter: | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Page Range: | pp. 3699-707 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date: | 2004 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institutions: | Medicine > Lehrstuhl für Chirurgie Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Identification Number: |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Classification: |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Keywords: | SEVERE COMBINED IMMUNODEFICIENCY; TUMOR-CELLS; NK CELLS; CYTOLYTIC ACTIVITY; RECEPTOR; HEAT-SHOCK-PROTEIN-70; HSP70; MOLECULES; STRESS; RECOGNITION; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Status: | Published | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Refereed: | Yes, this version has been refereed | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Created at the University of Regensburg: | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Item ID: | 14434 |
Abstract
Purpose: The 14 amino acid sequence (aa(450-463)) TKDNNLLGRFELSG (TKD) of heat shock protein 70 (Hsp70) was identified as a tumor-selective recognition structure for natural killer (NK) cells. Incubation of peripheral blood lymphocyte cells with TKD plus low-dose interleukin 2 (IL-2) enhances the cytolytic activity of NK cells against Hsp70 membrane-positive tumors, in vitro and in vivo. These ...

Abstract
Purpose: The 14 amino acid sequence (aa(450-463)) TKDNNLLGRFELSG (TKD) of heat shock protein 70 (Hsp70) was identified as a tumor-selective recognition structure for natural killer (NK) cells. Incubation of peripheral blood lymphocyte cells with TKD plus low-dose interleukin 2 (IL-2) enhances the cytolytic activity of NK cells against Hsp70 membrane-positive tumors, in vitro and in vivo. These data encouraged us to test tolerability, feasibility, and safety of TKD-activated NK cells in a clinical Phase I trial. Experimental Design: Patients with metastatic colorectal cancer (n = 11) and non-small cell lung cancer (n = 1) who had failed standard therapies were enrolled. After ex vivo stimulation of autologous peripheral blood lymphocytes with Hsp70-peptide TKD (2 mug/ml) plus low-dose IL-2 (100 units/ml), TKD was removed by extensive washing, and activated cells were reinfused i.v. The procedure was repeated for up to six cycles, applying a dose escalation schedule in 4 patients. Results: The percentage of activated NK cells in the reinfused leukapheresis products ranged between 8 and 20% of total lymphocytes, corresponding to total NK cell counts of 0.1 up to 1.5 x 10(9). Apart from restless feeling in I patient and itching in 2 patients, no negative side effects were observed. Concomitant with an enhanced CD94 cell surface density, the cytolytic activity of NK cells against Hsp70 membrane-positive colon carcinoma cells was enhanced after TKD/IL-2 stimulation in 10 of 12 patients. Concerning tumor response, 1 patient was in stable disease during therapy by formal staging criteria and another patient showed stable disease in one metastases and progression in another. Conclusions: Reinfusion of Hsp70-activated autologous NK cells is safe. Immunological results warrant additional studies in patients with lower tumor burden.
Metadata last modified: 15 Mar 2022 10:51